CMAB vs IMAB in Metastatic Prostate Cancer

Longitudinal, Randomized, Open and Prospective Clinical Trial to Evaluate the Efficacy of Continuous vs Intermittent Maximum Androgen Blockade (CMAB vs IMAB) With Goserelin-Bicalutamide Combination in the Treatment of Hormonal naïve With Metastatic Prostate Cancer

To evaluate the efficacy, safety and survival of two treatment regimens: Continuous Intermittent Maximum Androgen Blockade, using goserelin and bicalutamide in patients with prostate cancer. Primary endpoint is time to progression. Fifteen patients will be evaluated. QoL evaluation is also included.

Inclusion Criteria:

• Histological diagnosis of D2 of Adenocarcinoma,
• Naivety to treatment
• Valuable bone metastasis

Exclusion Criteria:

• Hematological, liver or renal toxicity Grade IV
• Severe and active infections